A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0385-0434 in Healthy Subjects and Patients With Hypercholesterolaemia
Latest Information Update: 04 May 2020
At a glance
- Drugs NNC0385 0434 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
Most Recent Events
- 29 Apr 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2020 Planned End Date changed from 3 Feb 2020 to 23 Apr 2020.